多肽偶联纳米颗粒在「人源化」HLA转基因小鼠中诱导耐受并抑制1型糖尿病致病性CD8+ T细胞反应
研究将500 nm羧基化聚苯乙烯珠(PSB)共价偶联HLA-A*02:01限制性免疫优势表位混合物,在HHD II小鼠中诱导抗原特异性耐受,并在NOD.β2m null HHD小鼠中预防糖尿病、在1型糖尿病患者中抑制致病性CTL反应。
要点
- 多肽-PSB通过CD4+CD25+调节性T细胞、抑制性T细胞活化和T细胞无能在HHD II小鼠中诱导抗原特异性耐受。
- 多肽-PSB经CD169+巨噬细胞来源CCL22快速产生,促进调节性T细胞和CD11c+树突状细胞活化与积聚。
- 多肽-PSB在「人源化」NOD.β2m null HHD小鼠中预防糖尿病,并抑制1型糖尿病患者的致病性CTL反应。
核心结论
- 研究首次证明多肽-PSB复合物可诱导T细胞耐受并阻止自身免疫过程,为1型糖尿病抗原特异性耐受策略提供有前景的平台。
研究设计与样本
- 将500 nm羧基化聚苯乙烯珠(PSB)共价偶联HLA-A*02:01限制性免疫优势表位混合物,经静脉注射给予HHD II小鼠,并在NOD.β2m null HHD小鼠中验证延缓疾病进程的效果,在1型糖尿病患者中验证对致病性HLA-A*02:01限制性CTL反应的作用。
主要发现
- 多肽-PSB在HHD II小鼠中诱导抗原特异性耐受,保护性免疫机制通过CD4+CD25+调节性T细胞功能、抑制性T细胞活化和T细胞无能介导。
- 多肽-PSB通过CD169+巨噬细胞来源的C-C基序趋化因子22(CCL22)快速产生,诱导调节性T细胞和CD11c+树突状细胞的活化与积聚。
- 多肽-PSB在「人源化」NOD.β2m null HHD小鼠中预防糖尿病,并抑制1型糖尿病患者的致病性CTL反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Induction of antigen-specific immunological tolerance may provide an attractive immunotherapy in the NOD mouse model but the conditions that lead to the successful translation to human type 1 diabetes are limited. In this study, we covalently linked 500 nm carboxylated polystyrene beads (PSB) with a mixture of immunodominant HLA-A*02:01-restricted epitopes (peptides-PSB) that may have high clinical relevance in humans as they promote immune tolerance; we then investigated the effect of the nanoparticle-peptide complexes on T cell tolerance. METHODS: PSB-coupled mixtures of HLA-A*02:01-restricted epitopes were administered to HHD II mice via intravenous injection. The effects on delaying the course of the disease were verified in NOD.β2m null HHD mice. The diabetogenic HLA-A*02:01-restricted cytotoxic lymphocyte (CTL) responses to treatment with peptides-PSB were validated in individuals with type 1 diabetes. RESULTS: We showed that peptides-PSB could induce antigen-specific tolerance in HHD II mice. The protective immunological mechanisms were mediated through the function of CD4+CD25+ regulatory T cells, suppressive T cell activation and T cell anergy. Furthermore, the peptides-PSB induced an activation and accumulation of regulatory T cells and CD11c+ dendritic cells through a rapid production of CD169+ macrophage-derived C-C motif chemokine 22 (CCL22). Peptides-PSB also prevented diabetes in 'humanised' NOD.β2m null HHD mice and suppressed pathogenic CTL responses in people with type 1 diabetes. CONCLUSIONS/INTERPRETATION: Our findings demonstrate for the first time the potential for using multipeptide-PSB complexes to induce T cell tolerance and halt the autoimmune process. These findings represent a promising platform for an antigen-specific tolerance strategy in type 1 diabetes and highlight a mechanism through which metallophilic macrophages mediate the early cell-cell interactions required for peptides-PSB-induced immune tolerance.
引用
- Xu X, Bian L, Shen M, et al. Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes. Diabetologia. 2017. PMID: 28887632. doi:10.1007/s00125-017-4419-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。